Mr. Stephen Van Deventer reports

BIOGENE THERAPEUTICS WELCOMES PROFESSOR MIRELA DELIBEGOVIC, FRSE TO ITS SCIENTIFIC ADVISORY BOARD

Preveceutical Medical Inc.'s wholly owned subsidiary BioGene Therapeutics Inc. has appointed Prof. Mirela Dellbegovic, FRSE, to the scientific advisory board, effective Nov. 19, 2024.

Stephen Van Deventer, chief executive officer of BioGene, commented: "We are honoured to welcome Prof. Mirela Delibegovic to our scientific advisory board. Mirela's extensive research in obesity and diabetes physiology and signalling, coupled with her leadership in translational discovery, will provide invaluable insights as we advance our therapeutic programs. Her expertise aligns seamlessly with BioGene's mission to develop innovative solutions for metabolic health challenges."

About Prof. Delibegovic

Prof. Delibegovic is a distinguished academic and entrepreneurial research leader in biomedical sciences. She currently holds the Regius chair of physiology at the University of Aberdeen and serves as the director of the Aberdeen Cardiovascular and Diabetes Centre. With over 25 years of experience in the cardiometabolic field, her research focuses on the molecular mechanisms underlying diabetes and obesity and their complications, with an emphasis on translational discovery and therapeutic development.

Throughout her career, Prof. Delibegovic has initiated and developed constructive collaborations leading to key publications, significant sustainable financing and impactful translational research outcomes. Work developed through these collaborations was recently highlighted by the United Nations Academic Impact publication as the example of a successful collaboration between academia and industry. She has been recognized with numerous awards, including being elected a fellow of the Royal Society of Edinburgh (FRSE) in 2022. Her leadership extends to various national and international committees, reflecting her commitment to advancing biomedical research and innovation.

Prof. Delibegovic remarked on her appointment: "I am delighted to join BioGene's scientific advisory board and collaborate with a team dedicated to addressing critical unmet medical needs in cardiometabolic health. I look forward to contributing my expertise to support BioGene's innovative therapeutic initiatives."

About Preveceutical Medical Inc.

Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products. Preveceutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; nature-identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

About BioGene Therapeutics Inc.

BioGene is a Texas-based life science company focused on advancing innovative therapies in metabolic health and gene-based treatments. As a key component of BioGene's expansion, BioGene Australia operates as a wholly owned subsidiary of BioGene in Texas, leveraging the strategic benefits of Australia's 43.5-per-cent R&D tax cashback incentive. This subsidiary supports continuing research and development activities in Australia, where BioGene capitalizes on exceptional scientific talent and the nation's commitment to advancing life sciences. Currently, BioGene Australia is engaged in pioneering research into GLP-1 receptor agonists and advanced diabetes treatments, including gene therapies designed to address the growing global diabetes and obesity crisis.

We seek Safe Harbor.